BR112012002824A2 - agonistas de receptor de esfingosina-1-fosfato - Google Patents

agonistas de receptor de esfingosina-1-fosfato

Info

Publication number
BR112012002824A2
BR112012002824A2 BR112012002824A BR112012002824A BR112012002824A2 BR 112012002824 A2 BR112012002824 A2 BR 112012002824A2 BR 112012002824 A BR112012002824 A BR 112012002824A BR 112012002824 A BR112012002824 A BR 112012002824A BR 112012002824 A2 BR112012002824 A2 BR 112012002824A2
Authority
BR
Brazil
Prior art keywords
sphingosine
receptor agonists
phosphate receptor
phosphate
agonists
Prior art date
Application number
BR112012002824A
Other languages
English (en)
Portuguese (pt)
Inventor
L. Gilmore John
E. Sheppeck James
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BR112012002824A2 publication Critical patent/BR112012002824A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR112012002824A 2009-08-07 2010-08-06 agonistas de receptor de esfingosina-1-fosfato BR112012002824A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23205409P 2009-08-07 2009-08-07
PCT/US2010/044627 WO2011017578A1 (en) 2009-08-07 2010-08-06 Sphingosine-1-phosphate receptor agonists

Publications (1)

Publication Number Publication Date
BR112012002824A2 true BR112012002824A2 (pt) 2019-09-24

Family

ID=43029859

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002824A BR112012002824A2 (pt) 2009-08-07 2010-08-06 agonistas de receptor de esfingosina-1-fosfato

Country Status (19)

Country Link
US (1) US8399451B2 (enExample)
EP (1) EP2462139B1 (enExample)
JP (1) JP5602230B2 (enExample)
KR (1) KR20120108963A (enExample)
CN (1) CN102548989A (enExample)
AR (1) AR077819A1 (enExample)
AU (1) AU2010279354A1 (enExample)
BR (1) BR112012002824A2 (enExample)
CA (1) CA2770194A1 (enExample)
CL (1) CL2012000326A1 (enExample)
CO (1) CO6430439A2 (enExample)
EA (1) EA201270266A1 (enExample)
ES (1) ES2533095T3 (enExample)
MX (1) MX2012001160A (enExample)
PE (1) PE20120732A1 (enExample)
SG (1) SG177691A1 (enExample)
TW (1) TW201109323A (enExample)
WO (1) WO2011017578A1 (enExample)
ZA (1) ZA201200641B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049864A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
WO2011133734A1 (en) * 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
ES2539256T3 (es) 2010-07-20 2015-06-29 Bristol-Myers Squibb Company Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos
JP5869579B2 (ja) 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
WO2012061459A1 (en) * 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
TW202023386A (zh) * 2018-09-13 2020-07-01 瑞士商先正達合夥公司 殺有害生物活性唑-醯胺化合物
CN114181276A (zh) * 2021-12-17 2022-03-15 安徽大学 硫酯肽合成方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
JPS6480026A (en) 1987-09-21 1989-03-24 Mitsubishi Electric Corp Resist coater
DE4102024A1 (de) 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
DE69718194T2 (de) 1996-08-16 2003-10-16 Bristol-Myers Squibb Pharma Co., Wilmington Amidinophenyl-pyrrolidine, -pyrroline und -isoxazolidine und ihre derivate
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
EP1482895A4 (en) 2002-03-01 2005-04-27 Merck & Co Inc AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS
CA2483164C (en) 2002-04-23 2011-06-07 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
AU2003276043A1 (en) 2002-06-17 2003-12-31 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
US7220734B2 (en) 2002-12-20 2007-05-22 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists
EP1594508B1 (en) 2003-02-11 2012-08-08 Irm Llc Novel bicyclic compounds and compositions
EP1625123A4 (en) 2003-05-15 2007-08-29 Merck & Co Inc 3- (2-AMINO-1-AZACYCLYL) -5-ARYL-1,2,4-OXADIAZOLE AS S1P RECEPTOR AGONISTS
AU2004240649A1 (en) 2003-05-19 2004-12-02 Irm, Llc Immunosuppressant compounds and compositions
EP2644195A1 (en) 2003-05-19 2013-10-02 Irm Llc Immunosuppressant Compounds and Compositions
EP1644367B1 (en) 2003-05-19 2015-10-14 Novartis AG Immunosuppressant compounds and compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CA2539438A1 (en) 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
JP4773972B2 (ja) 2003-12-17 2011-09-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
BRPI0607435A2 (pt) 2005-02-14 2010-04-06 Univ Virginia composto ou um sal ou éster farmaceuticamente aceitável do mesmo, e, uso de um composto
BRPI0609515A8 (pt) 2005-03-23 2017-12-26 Actelion Pharmaceuticals Ltd Composto, composição farmacêutica, e, uso de um composto
NZ562561A (en) 2005-03-23 2010-11-26 Actelion Pharmaceuticals Ltd Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
TW200642683A (en) 2005-04-22 2006-12-16 Sankyo Co Heterocyclic compound
JP2008545767A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用
EP1896446A1 (en) 2005-06-24 2008-03-12 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
US20090221547A1 (en) 2005-08-23 2009-09-03 Irm Llc Immunosuppressant Compounds and Compositions
TW200800911A (en) 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
AU2006317689B2 (en) 2005-11-23 2013-07-25 Epix Delaware, Inc. S1P receptor modulating compounds and use thereof
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
EP2010524A2 (en) 2006-03-21 2009-01-07 Epix Delaware, Inc. S1p receptor modulating compounds
CA2648303C (en) 2006-04-03 2014-07-15 Astellas Pharma Inc. 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists
WO2008016674A1 (en) 2006-08-01 2008-02-07 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine- 1- phosphate receptor (slp)
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
KR101470659B1 (ko) 2006-09-07 2014-12-08 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-4-일 유도체
WO2008030843A1 (en) 2006-09-07 2008-03-13 Allergan, Inc. Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
AU2007293653B2 (en) 2006-09-08 2011-02-17 Novartis Ag N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
US8288554B2 (en) 2006-09-08 2012-10-16 Actelion Pharmaceuticals Ltd. Pyridin-3-yl derivatives as immunomodulating agents
EP2069318B1 (en) 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
KR20090057070A (ko) 2006-09-29 2009-06-03 노파르티스 아게 소염성 및 면역억제성을 갖는 옥사디아졸 유도체
NZ576893A (en) 2006-11-21 2012-01-12 Univ Virginia Patent Found Tetralin analogs having sphingosine 1-phosphate agonist activity
NZ577111A (en) 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
EP2120575A4 (en) 2006-12-21 2011-04-27 Abbott Lab AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
MX2009009597A (es) 2007-03-16 2009-09-16 Actelion Pharmaceuticals Ltd Derivados de amino-piridina como agonistas del receptor s1p1/edg1.
WO2008128951A1 (en) 2007-04-19 2008-10-30 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
MX2010003614A (es) 2007-10-04 2010-04-21 Merck Serono Sa Compuestos de diarilo oxadiazol.
CA2696863C (en) 2007-10-04 2016-10-18 Anna Quattropani Oxadiazole derivatives
BRPI0818804A2 (pt) 2007-11-01 2015-04-22 Actelion Pharmaceuticals Ltd Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
MX2010007026A (es) 2007-12-21 2010-10-05 Merck Serono Sa Derivados de triazoloxadiazoles.
EP2913326B1 (en) 2008-05-14 2020-07-15 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
WO2010041655A1 (ja) 2008-10-06 2010-04-15 昭和電工株式会社 触媒およびその製造方法ならびにその用途
WO2010065760A1 (en) 2008-12-04 2010-06-10 Exelixis, Inc. Imidazo [1,2a] pyridine derivatives, their use as s1p1 agonists and methods for their production
RU2490266C2 (ru) 2008-12-05 2013-08-20 Астеллас Фарма Инк. Соединение 2н-хромена и его производное
CN102245602B (zh) 2008-12-18 2014-09-10 默克雪兰诺有限公司 用于治疗多发性硬化症的与恶二唑稠合的杂环衍生物
AR075319A1 (es) 2008-12-23 2011-03-23 Novartis Ag Compuestos de biaril- bencil-amina, procesos para su produccion, su uso como productos farmaceuticos, y composiciones farmaceuticas que los comprenden
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
JP2012515789A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体
EP2389377B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
JP5669363B2 (ja) 2009-03-31 2015-02-12 昭和電工株式会社 樹脂組成物及びこれで処理された紙又は繊維加工品
US8724509B2 (en) 2009-04-03 2014-05-13 Panasonic Corporation Mobile communication method, mobile communication system, and corresponding apparatus

Also Published As

Publication number Publication date
US8399451B2 (en) 2013-03-19
SG177691A1 (en) 2012-02-28
TW201109323A (en) 2011-03-16
CO6430439A2 (es) 2012-04-30
PE20120732A1 (es) 2012-06-20
CL2012000326A1 (es) 2012-10-19
EA201270266A1 (ru) 2012-07-30
CA2770194A1 (en) 2011-02-10
EP2462139A1 (en) 2012-06-13
KR20120108963A (ko) 2012-10-05
WO2011017578A1 (en) 2011-02-10
EP2462139B1 (en) 2015-01-14
AU2010279354A1 (en) 2012-02-09
ZA201200641B (en) 2013-06-26
CN102548989A (zh) 2012-07-04
JP2013501729A (ja) 2013-01-17
MX2012001160A (es) 2012-02-13
ES2533095T3 (es) 2015-04-07
US20110190255A1 (en) 2011-08-04
AR077819A1 (es) 2011-09-28
JP5602230B2 (ja) 2014-10-08

Similar Documents

Publication Publication Date Title
FIC20250029I1 (fi) neratinibi
LTPA2020513I1 (lt) S1P receptoriaus agonisto dozavimas
FIC20230025I1 (fi) neratinibi
BRPI1015921A2 (pt) agonistas de gpr119
EP2490709A4 (en) PEPTIDIC GLP-2 AGONISTS
BR112012000937A2 (pt) dispositivo de conexão
BR112012000107A2 (pt) receptores de células t.
BR112012005782A2 (pt) dispositivo de conexão
AT10812U2 (de) Prüfstandsanordnung
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
IL218649A0 (en) Oxytocin receptor agonists
AT10813U2 (de) Prüfstandsanordnung
BRPI0915781A2 (pt) oxazolopiridimas como agonista do receptor edg-1
BR112012002824A2 (pt) agonistas de receptor de esfingosina-1-fosfato
EP2503066A4 (en) CONSTRUCTION MACHINE
FR2947857B1 (fr) Agencement de deshuileur
DK2516406T3 (da) Mglu2-agonister
BR112012007885A2 (pt) dispositivo de retensão
ITPD20090053U1 (it) Paradordi per banchine
BRPI0917563A2 (pt) porta-objeto
EP2394990A4 (en) INDOLINE DERIVATIVES
BR112012005119A2 (pt) novos antagonistas de hepcidina etanodiaminas
DE112010001133B8 (de) Schmiervorrichtung
DK2210985T3 (da) Forbindelsesindretning
EP2485753A4 (en) VARIANTS OF THE CHAPERONINE IN POSITION 10

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.